Analyst Price Targets — LGND
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 4:31 pm | Joseph Pantginis | H.C. Wainwright | $239.00 | $190.86 | TheFly | Ligand price target raised to $239 from $231 at H.C. Wainwright |
| December 10, 2025 12:09 pm | — | Stifel Nicolaus | $230.00 | $185.83 | TheFly | Ligand price target raised to $230 from $220 at Stifel |
| December 10, 2025 11:54 am | Trevor Allred | Oppenheimer | $275.00 | $185.83 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Ligand Pharma (LGND) |
| November 6, 2025 8:07 pm | Annabel Samimy | Stifel Nicolaus | $220.00 | $208.22 | StreetInsider | Ligand Pharma (LGND) PT Raised to $220 at Stifel |
| November 6, 2025 5:32 pm | — | H.C. Wainwright | $231.00 | $204.50 | TheFly | Ligand price target raised to $231 from $206 at H.C. Wainwright |
| November 3, 2025 12:37 pm | Leland Gershell | Oppenheimer | $250.00 | $192.97 | TheFly | Ligand price target raised to $250 from $190 at Oppenheimer |
| September 3, 2025 11:37 am | Leland Gershell | Oppenheimer | $190.00 | $165.76 | TheFly | Ligand price target raised to $190 from $167 at Oppenheimer |
| August 28, 2025 2:34 pm | — | H.C. Wainwright | $206.00 | $158.93 | TheFly | Ligand price target raised to $206 from $157 at H.C. Wainwright |
| February 28, 2025 1:32 pm | — | UBS | $155.00 | $122.23 | TheFly | Ligand price target raised to $155 from $143 at RBC Capital |
| October 21, 2024 6:54 am | Joseph Pantginis | H.C. Wainwright | $157.00 | $108.31 | StreetInsider | Ligand Pharma (LGND) PT Raised to $157 at H.C. Wainwright |
Latest News for LGND
JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference (Miami): Management will participate in one-on-one meetings March 11, 2026 38 th Annual ROTH Conference (Dana Point, Calif.
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share 1 of $8.00-$9.00 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla.
CenterBook Partners LP lowered its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 52.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,434 shares of the biotechnology company's stock after selling 7,033 shares during the quarter. CenterBook
JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LGND.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.